Michael D. Lock

2.1k citations

40 papers · 1.7k · 1 hit paper · h-index 18

Impact in

Endocrinology top 2%
- Vibrio bacteria research studies
- Escherichia coli research studies
Psychiatry and Mental health top 2%
- Epilepsy research and treatment

Papers in

Endocrinology 13
- Vibrio bacteria research studies 13
- Escherichia coli research studies 5
Psychiatry and Mental health 12
- Epilepsy research and treatment 12

Co-authors: Marc Gurwith (11 shared papers)Bradley S. Galer (12 shared papers)Anupam Agarwal (9 shared papers)Gail M. Farfel (11 shared papers)Kelly G. Knupp (8 shared papers)Arnold R. Gammaitoni (10 shared papers)Lieven Lagae (10 shared papers)Glenn Morrison (6 shared papers)
Journals: Vaccine (5 papers)Epilepsia (4 papers)Clinical and Vaccine Immunology (4 papers)American Journal of Tropical Medicine and Hygiene (3 papers)Epilepsy & Behavior (2 papers)
Partner nations: United States Belgium France

In The Last Decade

Michael D. Lock

40 papers receiving 1.6k citations

Michael D. Lock's Hit Papers

align trajectories log scale

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial 2019 · 302 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2019 The Lancet

Peers

Countries citing papers authored by Michael D. Lock

Since Specialization

Citations

This map shows the geographic impact of Michael D. Lock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Lock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Lock more than expected).

Fields of papers citing papers by Michael D. Lock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Lock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Lock. The network helps show where Michael D. Lock may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael D. Lock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael D. Lock Line = papers co-authored together Michael D. Lock links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial The Lancet ·Lieven Lagae, Joseph E. Sullivan, Kelly G. Knupp, Linda Laux, Tilman Polster, Marina Nikanorova, Orrin Devinsky, Judith Helen Cross Hit paper breakdown →	2019	302
2	Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens JAMA Neurology ·Rima Nabbout, Arun Mistry, Sameer M. Zuberi, Nathalie Villeneuve, Antonio Gil-Nagel MD PhD, Rocı́o Sánchez-Carpintero, Ulrich Stephani, Linda Laux	2019	203
3	Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor Clinical Infectious Diseases ·Wilbur H. Chen, Mitchell B. Cohen, Beth D. Kirkpatrick, Rebecca C. Brady, David P. Galloway, Marc Gurwith, ROBERT H. HALL, Robert A. Kessler	2016	155
4	Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study The Lancet Infectious Diseases ·Marc Gurwith, Michael D. Lock, Eve M. Taylor, Glenn Y. Ishioka, Jeff Alexander, Tim Mayall, John E. Ervin, Richard Neil Greenberg	2013	137
5	Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome JAMA Neurology ·Kelly G. Knupp, Ingrid Eileen Scheffer, Berten Ceulemans, Joseph E. Sullivan, Katherine C. Nickels, Lieven Lagae, Renzo Guerrini, Sameer M. Zuberi	2022	102
6	Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial Vaccine ·Geoffrey J. Gorse, W Keitel, HARRY L. KEYSERLING, D TAYLOR, Michael D. Lock, Kristen Alves, Julie Kenner, Lynne Deans	2006	94
7	Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome Seizure ·Judith Helen Cross, Bradley S. Galer, Antonio Gil-Nagel MD PhD, Orrin Devinsky, Berten Ceulemans, Lieven Lagae, An‐Sofie Schoonjans, Elizabeth J Donner	2021	68
8	Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study Epilepsia ·Joseph E. Sullivan, Ingrid Eileen Scheffer, Lieven Lagae, Rima Nabbout, Milka Pringsheim, Dinesh Talwar, Tilman Polster, Bradley S. Galer	2020	61
9	PaxVax CVD 103-HgR single-dose live oral cholera vaccine Expert Review of Vaccines ·Myron Levine, Wilbur H. Chen, James B. Kaper, Michael D. Lock, Lisa E. Danzig, Marc Gurwith	2017	57
10	Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge Vaccine ·Cyril J. Empig, Julie Kenner, Marcel Perret-Gentil, Bryan E. Youree, Edward F. Bell, Allen Menglin Chen, Marc Gurwith, Keith W. Higgins	2005	52
11	Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks Clinical and Vaccine Immunology ·Wilbur H. Chen, Richard Neil Greenberg, Marcela F. Pasetti, Sofie Livio, Michael D. Lock, Marc Gurwith, Myron Levine	2013	47
12	Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study Epilepsia ·Kelly G. Knupp, Ingrid Eileen Scheffer, Berten Ceulemans, Joseph E. Sullivan, Katherine C. Nickels, Lieven Lagae, Renzo Guerrini, Sameer M. Zuberi	2022	43
13	Model-Free Curve Estimation. Biometrics ·Michael C. Jones, Michael E. Tarter, Michael D. Lock	1994	40
14	Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial Epilepsia ·Joseph E. Sullivan, Lieven Lagae, Judith Helen Cross, Orrin Devinsky, Renzo Guerrini, Kelly G. Knupp, Linda Laux, Marina Nikanorova	2023	39
15	Antibody-Based Correlates of Protection against Cholera: Analysis of a Challenge Study of a Cholera-Naive Population Clinical and Vaccine Immunology ·Douglas J. Haney, Michael D. Lock, Jakub K. Simon, Jason B. Harris, Marc Gurwith	2017	28
16	Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers PLoS neglected tropical diseases ·Kamrul Islam, M. Anowar Hossain, Meagan Kelly, Leslie M. Mayo Smith, Richelle C. Charles, Md Taufiqur Rahman Bhuiyan, Pavol Kováč, Peng Xu	2018	28
17	Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation Inflammation ·Manish Kumar Jain, Mukundan G Attur, Vika Furer, John A. Todd, R. Flores Ramírez, Michael D. Lock, Quynh Anh Lu, Steven B. Abramson	2014	26
18	Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection Vaccine ·Douglas J. Haney, Michael D. Lock, Marc Gurwith, Jakub K. Simon, Glenn Y. Ishioka, Mitchell B. Cohen, Beth D. Kirkpatrick, Caroline E. Lyon	2018	23
19	Treatment with fenfluramine in patients with Dravet syndrome has no long-term effects on weight and growth Epilepsy & Behavior ·Antonio Gil-Nagel MD PhD, Joseph E. Sullivan, Berten Ceulemans, Elaine C. Wirrell, Orrin Devinsky, Rima Nabbout, Kelly G. Knupp, Michael Scott Perry	2021	17
20	The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae Clinical and Vaccine Immunology ·Leslie M. Mayo-Smith, Jakub K. Simon, Wilbur H. Chen, Douglas J. Haney, Michael D. Lock, Caroline E. Lyon, Stephen B. Calderwood, Beth D. Kirkpatrick	2016	17

About Michael D. Lock

Michael D. Lock is a scholar working on Endocrinology, Psychiatry and Mental health, Epidemiology, Infectious Diseases and Virology, having authored 40 papers that have together received 1.7k indexed citations. Recurring topics across this work include Vibrio bacteria research studies (13 papers), Epilepsy research and treatment (12 papers), Influenza Virus Research Studies (6 papers), Escherichia coli research studies (5 papers), Child Nutrition and Water Access (3 papers), Pharmacological Effects and Toxicity Studies (2 papers), Viral Infections and Outbreaks Research (2 papers) and Virus-based gene therapy research (2 papers). The work is most often cited by research in Endocrinology (304 citations), Psychiatry and Mental health (688 citations), Virology (99 citations), Pediatrics, Perinatology and Child Health (288 citations) and Infectious Diseases (249 citations). Michael D. Lock has collaborated with scholars based in United States, Belgium and France. Frequent co-authors include Marc Gurwith, Bradley S. Galer, Anupam Agarwal, Gail M. Farfel, Kelly G. Knupp, Arnold R. Gammaitoni, Lieven Lagae, Glenn Morrison, Berten Ceulemans and Joseph E. Sullivan. Their work appears in journals such as Vaccine, Epilepsia, Clinical and Vaccine Immunology, American Journal of Tropical Medicine and Hygiene and Epilepsy & Behavior.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Michael D. Lock

Impact in

Papers in i

In The Last Decade

Michael D. Lock

Michael D. Lock's Hit Papers

Peers

Countries citing papers authored by Michael D. Lock

Fields of papers citing papers by Michael D. Lock

All Works

About Michael D. Lock

Explore authors with similar magnitude of impact

Papers in